Drug Profile

CPTX 2309

Alternative Names: ABBV-619; CPTX-2309

Latest Information Update: 28 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Capstan Therapeutics
Developer AbbVie
Class Gene therapies; Immunotherapies; RNA
Mechanism of Action T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Autoimmune disorders

Most Recent Events

24 Oct 2025 Pharmacodynamics data from a preclinical trial in Autoimmune disorder presented at the ACR Convergence 2025 (ACR/ARP-2025)
19 Aug 2025 Capstan Therapeutics has been acquired by AbbVie
30 Jun 2025 AbbVie will acquires CPTX 2309 from Capstan Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com